Overview: CD MPO Flow Cytometry TestIntroduction: The CD MPO Flow Cytometry Test detects myeloperoxidase (MPO) markers to diagnose leukemia, causing fatigue or easy bruising. Aligned with 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected leukemia.
Other Names: MPO Flow Assay, Myeloperoxidase Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: MPO testing began in the 1980s with leukemia research. Flow cytometry emerged in the 1990s, and standardized panels improved accuracy by the 2000s.
Purpose: Diagnoses leukemia, guides treatment, and monitors MPO markers in patients with fatigue or easy bruising.
Test Parameters: 1. Myeloperoxidase (MPO)
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or easy bruising, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, easy bruising, or history of leukemia. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect MPO markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express MPO.
Clinical Significance: Positive MPO expression suggests leukemia, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers (e.g., CD33, CD13), or cytogenetic testing to confirm leukemia.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Arber DA, 2022.
